SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
06 nov. 2024 17h05 HE
|
SAB Biotherapeutics, Inc.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
31 oct. 2024 07h00 HE
|
SAB Biotherapeutics, Inc.
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference
08 janv. 2024 09h00 HE
|
Kriya Therapeutics, Inc.
– Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...
TNDM Shareholder Alert: Investors with Large Losses Should Contact Robbins LLP for Information About Recovery Against Tandem Diabetes Care, Inc.
21 sept. 2023 18h52 HE
|
Robbins LLP
SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Tandem Diabetes...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
22 août 2022 07h12 HE
|
Resverlogix Corp
CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse...
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients
25 juin 2021 11h30 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...
Nemaura Medical Launches BEAT®diabetes Program and Its Novel proBEAT™ Non-Invasive, Daily-Wear Adhesive Glucose Monitor
17 déc. 2020 08h00 HE
|
Nemaura Medical Inc.
LOUGHBOROUGH, England, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
Nemaura Medical Licenses Validated Mobile Application to Create Powerful Diabetes Prevention and Management Suite of Products
21 sept. 2020 08h00 HE
|
Nemaura Medical Inc.
Clinically proven app from Healthimation, LLC, to be paired with Company’s proBEAT™ non-invasive CGM system solution to offer convenient and effective management of pre-diabetes and Type 2 diabetes ...
Dawson James Securities Announces Closing of $2.0 Million Offering for Nemaura Medical, Inc.
20 déc. 2018 15h37 HE
|
Dawson James Securities, Inc.
BOCA RATON, Fla., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Dawson James Securities, Inc. in conjunction with Nemaura Medical (Nasdaq: NMRD) announced today the closing of a public offering of 1,942,061...
NovuHealth Research Confirms that Engagement Drives Healthy Activities among Low-Income Consumers
01 août 2018 14h24 HE
|
NovuHealth
MINNEAPOLIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- NovuHealth, the healthcare industry’s leading consumer engagement company, has released new research that illustrates the effectiveness of engagement...